Cotización Amneal Pharmaceuticals - AMRX

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

5.87

Postura de Compra

Postura de Venta

Volume Operado de la Acción

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

1.817B

Precio Anterior

5.87

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

309,542,608

Rendimiento del Dividendo

Ratio Precio/Utilidad

-21.64

Beneficio por acción (BPA)

-0.27

turnover

2.41B

Beneficio neto

-83.99M

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inha... Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.amneal.com

Sede

Wilmington, Delaware, USA

Fundado

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Represents Amneal’s fourth 505(b)(2) injectable approval in 2024 Ready-to-use oncology treatment used for multiple myeloma and mantle cell...

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables...

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables...

Form 144 - Report of proposed sale of securities

Amneal Reports Second Quarter 2024 Financial Results

‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million;...

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

AMRX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Amneal Pharmaceuticals?

El precio actual de las acciones de Amneal Pharmaceuticals es US$ 5.87

¿Cuántas acciones de Amneal Pharmaceuticals están en circulación?

Amneal Pharmaceuticals tiene 309,542,608 acciones en circulación

¿Cuál es la capitalización de mercado de Amneal Pharmaceuticals?

La capitalización de mercado de Amneal Pharmaceuticals es USD 1.82B

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Amneal Pharmaceuticals?

Amneal Pharmaceuticals ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Amneal Pharmaceuticals?

El ratio precio/beneficio de Amneal Pharmaceuticals es -21.64

¿Cuál es el ratio de efectivo a ventas de Amneal Pharmaceuticals?

El ratio de efectivo a ventas de Amneal Pharmaceuticals es 0.75

¿Cuál es la moneda de reporte de Amneal Pharmaceuticals?

Amneal Pharmaceuticals presenta sus resultados financieros en USD

¿Cuál es el último ingresos anual de Amneal Pharmaceuticals?

El último ingresos anual de Amneal Pharmaceuticals es USD 2.41B

¿Cuál es el último beneficio anual de Amneal Pharmaceuticals?

El último beneficio anual de Amneal Pharmaceuticals es USD -83.99M

¿Cuál es la dirección registrada de Amneal Pharmaceuticals?

La dirección registrada de Amneal Pharmaceuticals es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

¿Cuál es la dirección del sitio web de Amneal Pharmaceuticals?

La dirección del sitio web de Amneal Pharmaceuticals es www.amneal.com

¿En qué sector industrial opera Amneal Pharmaceuticals?

Amneal Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Símbolo	Precio	Vol.
APAmpco Pittsburgh Corp	US$ 2.19 (22.35%)	80.61k
QBTSD Wave Quantum Inc	US$ 6.901 (18.57%)	130.86M
IHiHuman Inc	US$ 2.60 (17.65%)	280.32k
WDHWaterdrop Inc	US$ 1.495 (14.12%)	671.09k
YSGYatsen Holding Limited	US$ 4.90 (13.69%)	473.84k
TLYSTillys Inc	US$ 2.54 (-23.03%)	625.12k
NOVASunnova Energy International Inc	US$ 0.3031 (-17.46%)	40.96M
KUKEKuke Music Holding Limited	US$ 2.00 (-16.39%)	465.69k
ATENA10 Networks Inc	US$ 16.375 (-16.24%)	6.66M
PATHUiPath Inc	US$ 9.96 (-15.81%)	49.5M
FFord Motor Company	US$ 9.535 (-0.57%)	137.74M
QBTSD Wave Quantum Inc	US$ 6.901 (18.57%)	130.86M
NIONIO Inc	US$ 4.735 (-7.16%)	64.24M
BTEBaytex Energy Corporation	US$ 2.055 (-3.52%)	59.55M
BBDBanco Bradesco SA	US$ 2.03 (1.50%)	53.5M

Símbolo

Precio

Vol.

FFord Motor Company

US$ 9.535

(-0.57%)

137.74M

QBTSD Wave Quantum Inc

US$ 6.901

(18.57%)

130.86M

NIONIO Inc

US$ 4.735

(-7.16%)

64.24M

BTEBaytex Energy Corporation

US$ 2.055

(-3.52%)

59.55M

BBDBanco Bradesco SA

US$ 2.03

(1.50%)

53.5M

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Amneal Pharmaceuticals Holding Co (AMRX)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Acerca de Amneal Pharmaceuticals Holding Co

AMRX Últimas noticias

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Amneal Reports Second Quarter 2024 Financial Results

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More

Amneal Reports Second Quarter 2024 Financial Results

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

AMRX - Preguntas Frecuentes

Movimientos

AMRX Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Amneal Pharmaceuticals Holding Co (AMRX) Cotización

Amneal Pharmaceuticals Holding Co (AMRX)

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Acerca de Amneal Pharmaceuticals Holding Co

AMRX Últimas noticias

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Amneal Reports Second Quarter 2024 Financial Results

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More

Amneal Reports Second Quarter 2024 Financial Results

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

AMRX - Preguntas Frecuentes

Movimientos

AMRX Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Quitar anuncios

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS